Corvidane: Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants.

1

CEO designed trials for Vascepa®, which reduces heart attack and stroke risk for high triglycerides.

2

Corvidane raised $360k from over 200 Investors in previous RegCF.

3

Corvidane granted ~$700k in non-dilutive grants for Research and Development.

4

Results of Corvida™'s effect on LDLr-/- mouse and genes associated with atherosclerosis due in 2023.

5

Corvida™ is protected by patents in the US, Japan and Brazil and are owned by the company.

6

Funds raised will lead to PreIND meetings with the FDA to ensure acceptability of human trials.

7

Corvida™'s components are designated GRAS (Generally Regarded as Safe) by the FDA.

8

This is an opportunity to impact global health and potentially realize significant financial gains.

Corvidane